# EDGAR Filing Document

**Accession Number:** 0000744218
**File Stem:** 0001104659-25-057066
**Filing Date:** 2025-6
**Character Count:** 18014
**Document Hash:** 04080294dc66562e3051861a926131a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-057066.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0001104659-25-057066

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250605

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Celldex Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0000744218
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 133191702
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-15006
- **FILM NUMBER:** 251028926

**BUSINESS ADDRESS:**
- **STREET 1:** 53 FRONTAGE ROAD
- **STREET 2:** SUITE 220
- **CITY:** HAMPTON
- **STATE:** NJ
- **ZIP:** 08827
- **BUSINESS PHONE:** 908-200-7500

**MAIL ADDRESS:**
- **STREET 1:** 53 FRONTAGE ROAD
- **STREET 2:** SUITE 220
- **CITY:** HAMPTON
- **STATE:** NJ
- **ZIP:** 08827

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AVANT IMMUNOTHERAPEUTICS INC
- **DATE OF NAME CHANGE:** 19980828

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** T CELL SCIENCES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(** **d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 5, 2025**

**Celldex Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **000-15006** | **13-3191702** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

**Perryville III Building, 53 Frontage Road, Suite 220, Hampton, New Jersey 08827**

(Address of principal executive offices) (Zip Code)

**(908) 200-7500**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $.001 | CLDX | Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 5, 2025 at the 2025 Annual Meeting of Stockholders (the "Annual Meeting") of Celldex Therapeutics, Inc. (the "Company"), the Company's stockholders approved an amendment (the "Plan Amendment") to the Company's 2021 Omnibus Equity Incentive Plan (the "2021 Plan") (i) increasing the number of shares available for issuance under the 2021 Plan by 2,000,000 shares. The Plan Amendment became effective following its approval by the Company's stockholders.

The foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 5, 2025, at the Annual Meeting, the stockholders voted on the four proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 21, 2025 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026. The tabulation of votes with respect to the election of such directors was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Nominees** | **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| Anthony S. Marucci (Chief Executive Officer) | 54056360 | 60785 | 164073 | 4031935 |
| Keith L. Brownlie | 53883737 | 250401 | 147080 | 4031935 |
| Cheryl L. Cohen | 53969213 | 165776 | 146229 | 4031935 |
| Herbert J. Conrad | 53051316 | 1082802 | 147100 | 4031935 |
| Rita I. Jain, M.D. | 53914572 | 207007 | 159639 | 4031935 |
| James J. Marino | 53832714 | 301247 | 147257 | 4031935 |
| Garry A. Neil, M.D. | 53900408 | 233807 | 147003 | 4031935 |
| Harry H. Penner, Jr. | 53773546 | 360343 | 147329 | 4031935 |
| Denice Torres | 54104937 | 29828 | 146453 | 4031935 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. The tabulation of votes with respect to this proposal was as follows:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| &nbsp;&nbsp;58,043,825 | &nbsp;&nbsp;119,347 | &nbsp;&nbsp;149,981 |

---

&nbsp;&nbsp;&nbsp;&nbsp;3. The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares. The tabulation of votes with respect to this proposal was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;53,158,156 | &nbsp;&nbsp;963,067 | &nbsp;&nbsp;159,995 | &nbsp;&nbsp;4,031,935 |

---

&nbsp;&nbsp;&nbsp;&nbsp;4. The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement. The tabulation of votes with respect to this proposal was as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Votes** |
| &nbsp;&nbsp;53,482,418 | &nbsp;&nbsp;626,666 | &nbsp;&nbsp;172,134 | &nbsp;&nbsp;4,031,935 |

---

With the election of the above-referenced board members on June 5, 2025, Karen Shoos's term of service on the Company's board of directors ended. The board of directors of the Company wishes to express its gratitude to Ms. Shoos for the dedication and guidance she has provided to the Company and its board of directors over the years. Subsequent to the Annual Meeting, the Company's board of directors convened on June 5, 2025 and elected Harry H. Penner, Jr., as Chair of the Company's board of directors.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| Exhibit No. | Description |
| [10.1](tm2517205d1_ex10-1.htm) | [Amendment No. 3 to Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan](tm2517205d1_ex10-1.htm) |
| [99.1](tm2517205d1_ex99-1.htm) | [Press Release, dated June 6, 2025](tm2517205d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CELLDEX THERAPEUTICS, INC.** | **CELLDEX THERAPEUTICS, INC.** |
| Dated: June 6, 2025 | By: | /s/ Sam Martin |
|  | Name: Sam Martin | Name: Sam Martin |
|  | Title: Senior Vice President and Chief Financial Officer | Title: Senior Vice President and Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**AMENDMENT No. 3 TO <br> CELLDEX THERAPEUTICS, INC.**

**2021 OMNIBUS EQUITY INCENTIVE PLAN**

**Dated: April 10, 2025**

This Agreement amends the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the "Plan"). All capitalized terms not defined herein shall have the meanings set forth in the Plan.

**R E C I T A L S**

WHEREAS, Section 17.2 of the Plan reserves to the Board of Directors ("Board") of Celldex Therapeutics, Inc. (the "Company") the right to amend the Plan from time to time; and

WHEREAS, the Board desires to amend the Plan to increase the number of shares available for awards under the plan by 2,000,000 shares in the manner hereinafter provided subject to approval by the Company's stockholders.

NOW THEREFORE, the Plan is hereby amended as follows:

*1.* *Amendment to Plan Share Limitation.* 

 

Section 4.1(a) of the Plan is amended and restated in its entirety as follows:

"(a) Subject to adjustment pursuant to Section 4.3 and any other applicable provisions hereof, the maximum aggregate number of shares of Common Stock which may be issued under all Awards granted to Participants under the Plan shall be (i) 9,500,000 shares plus (ii) such number of unused shares of Common Stock reserved under the Prior Plan as of the Effective Date, which unused reserve shall be rolled into this Plan (subsections (i) and (ii) together, the "Share Reserve"); all of which shares may, but need not, be issued in respect of Incentive Stock Options. In addition, there shall be rolled into this Plan and added to the Share Reserve (but not issued in respect of Incentive Stock Options) such number of shares of Common Stock subject to outstanding grants or awards under the Prior Plan as of the Effective Date which are thereafter forfeited, cancelled or otherwise lapse in accordance with the provisions of Section 4.1(b)."

2. *No Other Changes.* Except as set forth herein, the Plan shall remain in full force and effect without modification.

IN WITNESS WHEREOF, the undersigned, a duly authorized officer of the Company, has executed this Amendment as of the date first above written as evidence of its adoption by the Company.

---

| |
|:---|
| **CELLDEX THERAPEUTICS, INC.** |
| By: /s/ Sam Martin |
| Name: Sam Martin |
| Title: Senior Vice President and Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors**

**HAMPTON, N.J., June 6, 2025 --** Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company's Board of Directors.

"We are excited to welcome Denice to the Celldex Board of Directors," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex. "Denice's extensive leadership experience across both the pharmaceutical and consumer healthcare sectors brings a deep operational and commercial perspective to our team. Her track record of driving strategic growth and operational excellence will be instrumental as we advance our clinical programs and continue building our organization."

Ms. Torres added, "I am thrilled to join the board of Celldex, particularly at this exciting time in the Company's development. I am impressed by the significant progress Celldex has made with barzolvolimab and its potential to set a new treatment standard in a disease where patients desperately need better options. I look forward to contributing my expertise as we continue to advance."

Ms. Torres currently serves as Chief Executive Officer of The Ignited Company, a Pennsylvania-based consulting firm she founded in 2017. From 2009 to 2017, she served in various senior leadership roles at Johnson & Johnson (J&J). From 2015 to 2017, she was Chief Strategy and Transformation Officer for J&J's global medical device business, a $25 billion business with more than 50,000 employees. From 2011 to 2015, she was President of J&J McNeil Consumer Healthcare, where she led the recovery of OTC brands, including the iconic Tylenol portfolio, by transforming business operations, manufacturing, quality systems and commercialization approaches, and creating high levels of employee engagement across all functions of the business. From 2009 to 2011, she served as President of J&J Janssen Pharmaceuticals, Neuroscience, and from 2006-2009 she held various marketing positions at J&J. Ms. Torres was the sole recipient of the prestigious J&J HONOR award in 2016 for her work in diversity and inclusion, and she was named the 2015 Woman of the Year by the Healthcare Businesswomen's Association. Before joining J&J, Ms. Torres built a successful, 14-year career at Eli Lilly and Company, where she focused on marketing and business unit management. Ms. Torres has served on the Board of Directors of publicly traded companies 2seventybio and Glaukos since 2021. She previously served on the boards of Karuna Therapeutics, Inc., Surface Oncology and Bluebird bio, Inc., all publicly traded biopharmaceutical companies. She is also the founder of The Mentoring Place, a nonprofit organization offering free executive mentoring to help women achieve their careers goals. Ms. Torres holds a B.S. in Psychology from Ball State University, a J.D. from Indiana University, an M.B.A. from the University of Michigan and an M.A in the Study of Happiness from Centenary University. She is a member of the Michigan Bar Association.

**About Celldex Therapeutics, Inc.**

Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit <u>www.celldex.com</u>

**Forward Looking Statement**

This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

**Company Contact**

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

<u>scavanaugh@celldex.com</u>

Patrick Till

Meru Advisors

(484) 788-8560

<u>ptill@meruadvisors.com</u>